Please login to the form below

Not currently logged in
Email:
Password:

Richard Paulson joins Ipsen as CEO for North America

He also becomes an executive vice-president at the French biopharma

Richard PaulsonIpsen has appointed Richard Paulson as executive vice president and chief executive officer of North America, roles that will see him take responsibility for all commercial operations throughout the region.

Paulson, who joins from Amgen where he most recently served as vice president and general manage of he oncology business unit, will report directly to David Meek, Ipsen’s chief executive officer.

Meek said: “We are extremely delighted to welcome Richard to Ipsen to drive the continued growth of our North American business and further our development as a leading biopharma company focused on innovation and speciality care.

“Richard brings a wealth of great leadership experience, vision, and a track record of exceptional execution in leading growing businesses, both in the US and internationally.”

During a 10-year career at Amgen, Paulson held a number positions at the company, including general manager of Germany and general manager of central and eastern Europe.

Prior to his time at Amgen, Paulson served in many general management, marketing and market access positions at Pfizer.

He said: “I am honoured to join Ipsen at this time of rapid transformation and growth as the company progresses in its evolution as a leading global biopharma company.”

Paulson succeeds Cynthia Schwalm, who leaves Ipsen to pursue other interests.

19th January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics